Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA ...

Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous ...

A rare and fatal brain disorder with no available treatment or cure. One that attacks the nervous system, balance, and the ability to move.

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...

Multiple system atrophy (MSA) is a relentlessly progressive adult-onset synucleinopathy characterised by the intracytoplasmic accumulation of α-synuclein in oligodendrocytes, manifesting as glial ...

In 2020, Ashley Harms, Ph.D., and University of Alabama at Birmingham colleagues published an Acta Neuropathologica study that used a mouse model to show that the alpha-synuclein pathology from ...

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterised by a combination of parkinsonism, cerebellar ataxia and autonomic dysfunction. Clinical assessment ...